scholarly journals RESEARCH AND PATENTING IN COVID TIMES

INDIAN DRUGS ◽  
2020 ◽  
Vol 57 (08) ◽  
pp. 5-6
Author(s):  
Gopakumar G. Nair ◽  
Keyword(s):  
Natural Products ◽  
Learning Experience ◽  
Great Learning ◽  
Patent Rights ◽  
The Us ◽  
Dear Reader ◽  
Intellectual Properties

Dear Reader, Government of India is currently negotiating a limited trade deal with USA which is likely to be signed after the US elections. Although, the current negotiations do not cover the Intellectual Properties (IP) or Pharmaceuticals, a limited deal if concluded successfully is expected to be followed by a full Trade Deal (FTA), which will include IP and Pharmaceuticals too. In spite of all the negative (or positive?) consequences of COVID-19, the Sars2CoV virus has provided humanity with a great learning experience. Repurposing of known drugs, bio-natural products, biologicals and vaccines such as TB, Leprosy, BCG have all been undertaken in the desperate search for prophylactic, therapeutic as well as preventive options. However it is interesting to note and appreciate that except for pre-existing patent rights (ex:-Remdesivir), there have hardly been any emphases on protecting the Covid remedies through patenting.

scholarly journals The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Molecules ◽  
2020 ◽  
Vol 25 (3) ◽  
pp. 745 ◽  
Author(s):  
Beatriz G. de la Torre ◽  
Fernando Albericio
Keyword(s):  
Natural Products ◽  
Pharmaceutical Industry ◽  
Small Molecules ◽  
Chemical Structure ◽  
New Drugs ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
The Us ◽  
New Chemical Entities ◽  
Antibody Drug

During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved. Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019. This report analyzes the 48 new drugs of the class of 2019 from a strictly chemical perspective. The classification, which was carried out on the basis of chemical structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small molecules.

LETTERS: A Great Learning Experience

1974 ◽  
Vol 12 (5) ◽  
pp. 260-260
Author(s):  
W. A. Dempsey
Keyword(s):  
Learning Experience ◽  
Great Learning

AstraZeneca, Prilosec, and Nexium: Strategic Challenges in the Launch of a Second-Generation Drug

2017 ◽  
pp. 1-20 ◽  
Author(s):  
James G. Conley ◽  
Robert C. Wolcott ◽  
Eric Wong
Keyword(s):  
Intellectual Property ◽  
Product Life Cycle ◽  
Growth Strategy ◽  
Esophageal Reflux ◽  
Over The Counter ◽  
Revenue Growth ◽  
Pharmaceutical Firms ◽  
The Us ◽  
Intellectual Properties ◽  
Important Objective

Tom McKillop, CEO of AstraZeneca, faced the classic quandary of large pharmaceutical firms. Within the year, the firm's patent for Prilosec (active ingredient omeprazole) was expiring. Prilosec was a US$6.2 billion/year blockbuster that revolutionized the treatment of chronic gastro-esophageal reflux disorders (GERD). Severe cost-based competition from generic drug manufacturers was, however, inevitable. Patent expirations were nothing new for the US$15.8 billion in revenues drug firm. AstraZeneca had Nexium, an improvement on the original Prilosec molecule, in the pipeline. Ideally, it would like to move brand-loyal Prilosec customers to Nexium. Additionally, the company had the opportunity to introduce its own version of generic omeprazole, hence becoming the first mover in the generic segment, and/or introduce an over-the-counter (OTC) version of omeprazole. Tactically, AstraZeneca would like to use regulatory incentives and intellectual property rights to strengthen its competitive position. How could the company use its entire portfolio of intellectual properties—including patents and trademarks—to actively manage the priced-based competition and achieve a revenue growth strategy in the GERD market? An important objective of the case is to introduce students to the challenges of innovation and strategy in a regulated market environment. Additionally, students will learn the power of multiple forms of intellectual property used strategically along the product life cycle to build and sustain competitive advantage.

scholarly journals THE ROLE OF SERVICE LEARNING IN THE US STUDENTS’ CITIZENSHIP FORMATION

2020 ◽  
pp. 223-227
Author(s):  
Yuliia SHARANOVA ◽  
Keyword(s):  
Higher Education ◽  
Service Learning ◽  
Community Service ◽  
Learning Experience ◽  
Teaching Strategy ◽  
Rapid Change ◽  
The United States ◽  
Educational Process ◽  
The Us ◽  
The Usa

Introductain. The article highlights the ed-ucational potential of service learning in the US higher education in the process of forming students' citizenship. Teaching community service as a highly effective peda-gogical practice in American higher education institutions ensures the development of students' readiness for a meaningful and responsible life in an interdependent world characterized by uncertainty, rapid change and destabilizing inequality, and serves as a basis for forming students’ citizenship.The definition of community service learning by the American educators, who see it as a form of learning, as well as a teaching strategy that combines sociallysignifi-cant activities with an educational process based on reflection with the view to enriching students' learning experience, building civic responsibility and strengthening communities, is considered. The basic requirements of conformity of service learning in universities and colleges of the USA to the status of educational discipline are characterized.It is noted that teaching service learning in higher ed-ucation institutions in the United States promotes, through dialogue and cooperation, the social and cognitive devel-opment of students who, coming from the comfort zone to the contact zone, learn to interact effectively with each other and other people as well

Flipped Classroom

2017 ◽  
pp. 141-152
Author(s):  
Kijpokin Kasemsap
Keyword(s):  
Learning Environment ◽  
Learning Environments ◽  
Flipped Classroom ◽  
Learning Experience ◽  
Digital Age ◽  
Educational Performance ◽  
Great Learning ◽  
Video Lectures ◽  
Modern Learning ◽  
Online Sources

This chapter indicates the advanced issues of flipped classroom and the important perspectives on flipped classroom in the digital age. Flipped classroom is a learning environment where students learn new content on their own by watching video lectures or other online sources and assigned problems are completed in class with teachers offering personalized guidance instead of lectures. Flipped classroom allows students to learn on their own time and at their own pace and allows students to have more time for collaborating with other students which can be a great learning experience for the students and as a way for them to build their teamwork abilities. The chapter argues that utilizing flipped classroom has the potential to improve educational performance and facilitate the modern learning environments.

Innovation Management in Contemporary Organizations

2018 ◽  
Author(s):  
YUSUF GEZER
Keyword(s):  
Strategic Management ◽  
Business Model ◽  
Innovation Management ◽  
Learning Experience ◽  
Innovation Process ◽  
End Users ◽  
Business Model Innovation ◽  
Great Learning ◽  
Innovative Strategies ◽  
Innovative Concept

Adopting innovation and aligning with the modern day technology has always been a key to success for mankind. Throughout the course of this project it has been a great learning experience for me and I came across interesting findings and evidences that were the last thing I could have expected. This research has opened for me new gates of experiences and knowledge of other in areas like Managing the innovation process, different kinds of innovation and their implications for businesses, how to form strategic management for innovation, how researchers developed business model innovation and how technology has been influential in shaping innovative strategies. Worth mentioning finding of the research were the theories of “perceived compatibility” by Volberda and the technology accepting model, perfectly aligning itself with the human psychology. How customers would behave with a new idea and an innovative concept and to what extent and with what ease would they be willing to go for the innovation and help in making the idea a success. This is of core importance for all entrepreneurs as all they do and their achievement lies at the hands of the end users and as long as they are satisfied the innovative.

The US National Cancer Institute’s natural products repository; origins and utility

2006 ◽  
Vol 8 (8) ◽  
pp. 800-805 ◽  
Author(s):  
Erma C. Brown ◽  
David J. Newman
Keyword(s):  
Natural Products ◽  
The Us

Pharmacist's practice related to the use of natural products in the US – What is happening now?

2019 ◽  
Vol 6 ◽  
pp. S146
Author(s):  
Shane Desselle ◽  
Joanna Harnett ◽  
Mustafa Sultani ◽  
Ryan Hoh ◽  
Muhamod Saied ◽  
...  
Keyword(s):  
Natural Products ◽  
The Us

scholarly journals Using coaching tools to develop professional practice holistically

2020 ◽  
Vol 37 (3) ◽  
pp. 111-115
Author(s):  
Sarah Wolfenden
Keyword(s):  
Professional Practice ◽  
Learning Experience ◽  
Self Care ◽  
Good Measure ◽  
Great Learning ◽  
Space And Time ◽  
Starting Point ◽  
Training Professionals ◽  
Professional Accreditation ◽  
And Training

Do you teach or train others? Are you passionate about delivering a great learning experience to them? Are you considering working towards professional accreditation and have been putting it off? Are you tired of faffing around and want to get your focus back? Are you ambitious but concerned about burning out? Do you need some space and time – where no-one is vying for your attention – to gain clarity, develop your practice and explore how you can be of service to your participants, your colleagues and your loved ones while not losing yourself in the process? If the answer to any of these questions is yes, then you may find this article helpful. Its aim is to provide an overview of a few select tools to help teaching and training professionals articulate their purpose, craft a teaching identity and philosophy, and get the most out of training received – with a few self-care tips thrown in for good measure! As we move to a world where increasingly roles are being replaced by automation, we need to focus on what makes us individual, personalised humans (Gleeson, 2018). I hope that this article will provide a starting point.

scholarly journals Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Ryan Bradley ◽  
Blake O. Langley ◽  
Jennifer J. Ryan ◽  
John Phipps ◽  
Douglas A. Hanes ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Natural Products ◽  
Chronic Disease ◽  
Phase I ◽  
Healthy Adults ◽  
Phase I Clinical Trial ◽  
Gut Permeability ◽  
Cell Counts ◽  
The Us

Abstract Background Natural products may provide a source for the discovery and development of adjunctive pharmacological interventions to modulate the inflammatory pathways contributing to chronic disease. Xanthohumol, a flavonoid from the hops plant (Humulus lupulus), has antioxidant and anti-inflammatory properties and may act as a prebiotic to the intestinal microbiota. Xanthohumol is not currently approved as a drug by the US Food and Drug Administration (FDA), but is available as a dietary supplement and ingredient in medical foods. To formally test the safety of xanthohumol, a phase I clinical trial (“XMaS”) was designed and approved under an Investigational New Drug application to the US FDA. The main objective is to examine the clinical safety and subjective tolerability of xanthohumol in healthy adults compared to placebo. Additional aims are to monitor biomarkers related to inflammation, gut permeability, bile acid metabolism, routes, and in vivo products of xanthohumol metabolism, and to evaluate xanthohumol’s impact on gut microbial composition. Methods The safety and tolerability of xanthohumol in healthy adults will be evaluated in a triple-masked, randomized, placebo-controlled trial. Participants will be randomized to either 24 mg/day of xanthohumol or placebo for 8 weeks. Blood cell counts, hepatic and renal function tests, electrolytes, and self-reported health-related quality of life measures will be collected every 2 weeks. Participants will be queried for adverse events throughout the trial. Xanthohumol metabolites in blood, urine, and stool will be measured. Biomarkers to be evaluated include plasma tumor necrosis factor-alpha, various interleukins, soluble CD14, lipopolysaccharide-binding protein, fecal calprotectin, and bile acids to assess impact on inflammatory and gut permeability-related mechanisms in vivo. Stool samples will be analyzed to determine effects on the gut microbiome. Discussion This phase I clinical trial of xanthohumol will assess safety and tolerability in healthy adults, collect extensive biomarker data for assessment of potential mechanism(s), and provide comparison data necessary for future phase II trials in chronic disease(s). The design and robustness of the planned safety and mechanistic evaluations planned provide a model for drug discovery pursuits from natural products. Trial registration ClinicalTrials.gov NCT03735420. Registered on November 8, 2018

Sign in / Sign up

Export Citation Format

Share Document